Biotech SF

San Francisco Bay Area biotech stories.

Friday, October 5, 2012

GSK returns drug to Anacor

GlaxoSmithKline has stopped work on a compound from Anacor Pharmaceuticals Inc. after finding resistance among a "small number" of patients in a mid-stage trial in complicated urinary tract infections, Palo Alto-based Anacor said Friday.
Posted by Unknown at 11:53 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Anacor, GlaxoSmithKline

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

TOP STORIES

  • Patients' tales, biotech legends add weight to BayBio awards
    Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
  • Former Genentech exec Marc Tessier-Lavigne elected to Pfizer board
    Former Genentech Inc. chief scientific officer Marc Tessier-Lavigne was elected to Pfizer Inc.’s board of directors. Tessier-Lavigne, who j...
  • Stanford team wins $20K for algorithm aimed at Lou Gehrig's disease drug trials
    Lester Mackey. A team from Stanford University won $20,000 for its work with algorithms that could reduce the number of Lou Gehrig’s Dis...
  • Nation's HIV research general Tony Fauci: Cure in 'discovery phase'
    Dr. Tony Fauci. As director of the National Institute of Allergy and Infectious Diseases for the past 28 years, Tony Fauci has seen the ...
  • One-on-One with Roche Molecular Diagnostics' Paul Brown
    In the personalized medicine revolution, Roche Molecular Diagnostics is positioned to be the major arms supplier. The Pleasanton-based unit...

Some of my favorite stories.

• "The fight of his life" (2007)
Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)
Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)
Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)
Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.
All he needs now is $20 million.

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ▼  2012 (486)
    • ►  November (18)
    • ▼  October (25)
      • BioMarin licenses North American rights to rare di...
      • Neuraltus moving Lou Gehrig's disease drug into Ph...
      • How Massachusetts' Bluebird Bio tapped California'...
      • Gladstone, Stanford research offers new game plan ...
      • Ex-Codexis CEO unveils startup around enzymes to c...
      • BioMarin cuts ribbon on new San Rafael campus
      • Auxogyn teams with Merck Serono on in vitro fertil...
      • Alzheimer's drug failure translates into more job ...
      • Tria Beauty wins lawsuit against rival Oregon Aest...
      • Science, people first for biotech investor Bill Bowes
      • Genentech to 'gross up' to cover taxed benefits fo...
      • Longitude Capital closes $385M life sciences fund
      • UCSF-led group lands $10M for study of advanced pr...
      • Shinya Yamanaka of Gladstone, UCSF wins Nobel Prize
      • Maker of sterile bags for drug companies cutting 9...
      • GSK returns drug to Anacor
      • Antibody drug maker KaloBios seeks $60M IPO
      • Genentech fires new shot at breast cancer
      • BioSeek nabs $46.7M, five-year EPA contract
      • 'Startup in a Box' program loses leader to consult...
      • California seeks three more iHubs, expands San Fra...
      • Report: Health care in S.F. a 'sleeping giant,' bu...
      • NuMedii lands 1st deal to spin drug data into prod...
      • UCSF nabs $3 million to lead artificial kidney effort
      • XDx names former Novartis Emeryville chief Peter M...
    • ►  September (56)
    • ►  August (56)
    • ►  July (64)
    • ►  June (26)
    • ►  May (40)
    • ►  April (39)
    • ►  March (31)
    • ►  February (74)
    • ►  January (57)
  • ►  2011 (772)
    • ►  December (54)
    • ►  November (40)
    • ►  October (65)
    • ►  September (74)
    • ►  August (48)
    • ►  July (44)
    • ►  June (60)
    • ►  May (70)
    • ►  April (80)
    • ►  March (81)
    • ►  February (77)
    • ►  January (79)
  • ►  2010 (59)
    • ►  December (42)
    • ►  November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.
Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's
Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

  • "Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)
Unknown
View my complete profile

My contact information

Ron Leuty
San Francisco Business Times
275 Battery St.,
Suite 940
San Francisco,
CA 94111
415-288-4939 - direct
415-722-2678 - cell
rleuty@
bizjournals.com
http://www.bizjournals.com/sanfrancisco

Follow me on Twitter — rleuty_biotech
— or Facebook or LinkedIn.

For biotech stories from all of ACBJ's 40 business journals — from Boston to Seattle — go to Biotech Day.

Followers

Total Pageviews

Simple theme. Powered by Blogger.